Tumor regression grading after preoperative chemoradiotherapy as prognostic factor and individual-level surrogate for disease-free survival in rectal cancer: Results of the CAO/ARO/AIO-04 multicentre, open-label, randomised, phase 3 trial

被引：0

作者：

Fokas, E. ^{[1
]}

Stroebel, P. ^{[2
]}

Fietkau, R. ^{[3
]}

Ghadimi, M. ^{[4
]}

Liersch, T. ^{[4
]}

Grabenbauer, G. ^{[5
]}

Hartmann, A. ^{[6
]}

Kaufmann, M. ^{[7
]}

Sauer, R. ^{[3
]}

Graeven, U. ^{[8
]}

Hoffmanns, H. ^{[9
]}

Raab, H-R ^{[10
]}

Hothorn, T. ^{[7
]}

Wittekind, C. ^{[11
]}

Roedel, C. ^{[1
]}

机构：

[1] Goethe Univ Frankfurt, Klin Strahlentherapie & Onkol, Frankfurt, Germany

[2] Univ Klinikum Gottingen, Inst Pathol, Gottingen, Germany

[3] Univ Erlangen Nurnberg, Klin Strahlentherapie & Radioonkol, Erlangen, Germany

[4] Univ Klinikum Gottingen, Klin Allgemeinchirurg, Gottingen, Germany

[5] DiaCura & Klinikum Coburg, Klin Strahlentherapie & Radioonkol, Coburg, Germany

[6] Univ Klinikum Erlangen Nurnberg, Inst Pathol, Erlangen, Germany

[7] Univ Zurich, Epidemiol Biostat & Prevent Inst, Zurich, Switzerland

[8] Kliniken Maria Hilf GmbH, Klin Hamatol Onkol, Monchengladbach, Germany

[9] Kliniken Maria Hilf GmbH, Klin Strahlentherapie, Monchengladbach, Germany

[10] Univ Klinikum Oldenburg, Klin Allgemeinchirurg, Oldenburg, Germany

[11] Univ Klinikum Leipzig, Inst Pathol, Leipzig, Germany

来源：

STRAHLENTHERAPIE UND ONKOLOGIE | 2017年 / 193卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V11-1

引用

页码：S31 / S31

页数：1

共 25 条

[21] CT attenuation of liver metastases before targeted therapy is a prognostic factor of overall survival in colorectal cancer patients. Results from the randomised, open-label FIRE-3/AIO KRK0306 trial
Matthias F. Froelich
Volker Heinemann
Wieland H. Sommer
Julian W. Holch
Franziska Schoeppe
Nina Hesse
Alena B. Baumann
Wolfgang G. Kunz
Maximilian F. Reiser
Jens Ricke
Melvin D’Anastasi
Sebastian Stintzing
Dominik P. Modest
Philipp M. Kazmierczak
Felix O. Hofmann
European Radiology, 2018, 28 : 5284 - 5292
[22] CT attenuation of liver metastases before targeted therapy is a prognostic factor of overall survival in colorectal cancer patients. Results from the randomised, open-label FIRE-3/AIO KRK0306 trial
Froelich, Matthias F.
Heinemann, Volker
Sommer, Wieland H.
Holch, Julian W.
Schoeppe, Franziska
Hesse, Nina
Baumann, Alena B.
Kunz, Wolfgang G.
Reiser, Maximilian F.
Ricke, Jens
D'Anastasi, Melvin
Stintzing, Sebastian
Modest, Dominik P.
Kazmierczak, Philipp M.
Hofmann, Felix O.
EUROPEAN RADIOLOGY, 2018, 28 (12) : 5284 - 5292
[23] Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial
Al-Batran, Salah-Eddin
Hofheinz, Ralf D.
Pauligk, Claudia
Kopp, Hans-Georg
Haag, Georg Martin
Luley, Kim Barbara
Meiler, Johannes
Homann, Nils
Lorenzen, Sylvie
Schmalenberg, Harald
Probst, Stephan
Koenigsmann, Michael
Egger, Matthias
Prasnikar, Nicole
Caca, Karel
Trojan, Joerg
Martens, Uwe M.
Block, Andreas
Fischbach, Wolfgang
Mahlberg, Rolf
Clemens, Michael
Illerhaus, Gerald
Zirlik, Katja
Behringer, Dirk M.
Schmiegel, Wolff
Pohl, Michael
Heike, Michael
Ronellenfitsch, Ulrich
Schuler, Martin
Bechstein, Wolf O.
Koenigsrainer, Alfred
Gaiser, Timo
Schirmacher, Peter
Hozaeel, Wael
Reichart, Alexander
Goetze, Thorsten O.
Sievert, Mark
Jaeger, Elke
Moenig, Stefan
Tannapfel, Andrea
LANCET ONCOLOGY, 2016, 17 (12): : 1697 - 1708
[24] Adjuvant chemotherapy with oxaliplatin/5-fluorouracil/leucovorin (FOLFOX) versus 5-fluorouracil/leucovorin (FL) for rectal cancer patients whose postoperative yp stage 2 or 3 after preoperative chemoradiotherapy: Updated results of 3-year disease-free survival from a randomized phase II study (The ADORE).
Hong, Yong Sang
Nam, Byung-Ho
Kim, Kyu-Pyo
Lee, Jae-Lyun
Park, Joon Oh
Park, Young Suk
Kim, Sun Young
Kim, Tae-You
Kim, Jee Hyun
Ahn, Joong Bae
Jung, Kyung Hae
Kim, Tae Won
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[25] 3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial
Perez-Garcia, Jose Manuel
Cortes, Javier
Ruiz-Borrego, Manuel
Colleoni, Marco
Stradella, Agostina
Bermejo, Begona
Dalenc, Florence
Escriva-de-Romani, Santiago
Martinez, Lourdes Calvo
Ribelles, Nuria
Marme, Frederik
Cortes, Alfonso
Albacar, Cinta
Gebhart, Geraldine
Prat, Aleix
Kerrou, Khaldoun
Schmid, Peter
Braga, Sofia
Di Cosimo, Serena
Gion, Maria
Antonarelli, Gabriele
Popa, Crina
Szostak, Emilia
Alcala-Lopez, Daniel
Gener, Petra
Rodriguez-Morato, Jose
Mina, Leonardo
Sampayo-Cordero, Miguel
Llombart-Cussac, Antonio
LANCET, 2024, 403 (10437): : 1649 - 1659

← 1 2 3 →